The third report of the National Cholesterol Education Program guidelines recommend calculating the 10-year morbidity of atherosclerotic cardiovascular disease using risk calculators when treating high blood cholesterol in adults. We analyzed the changes in cardiovascular risk (CVR) among patients with human immunodeficiency virus (HIV) from M\u00e9xico.Materials and MethodsThis observational, prospective cohort study compared the cardiovascular risk after one year of usual treatment among 460 HIV patients in M\u00e9xico. Changes using the atherosclerotic cardiovascular disease risk estimator and changes in clinical outcomes were analyzed. The results were categorized as low or high CVR using a cut-off of 7.5%.The cardiovascular risk at baseline showed a mean of 4.45% \u00b1 6.1% (0.2% to 50.1%), which changed to 4.48% \u00b1 5.4% (0.2% to 33.2one year later . After cardiovascular risk stratification at baseline, we found that 84.3% of patients had a low CVR, and 18% of this group had metabolic syndrome. Moreover, 15.7% of this population was at high cardiovascular risk and 47% had metabolic syndrome. Approximately 4.3% of patients had a CVR increase and 2.6% had a cardiovascular risk decrease. Of the total patients, 22.3% had metabolic syndrome at baseline.